Posted by Michael Wonder on 15 Jan 2019
Approval for Seqirus flu vaccine
15 January 2019 - Seqirus has announced European approval of its new cell-based quadrivalent influenza vaccine.
The European Commission has approved Flucelvax Tetra, which will be the first cell-based quadrivalent influenza vaccine available in Europe, licensed for use in people nine years and above.
Cell-based technology represents one of the most significant changes in the way influenza vaccines are manufactured since the 1940s, and real-world data indicates cell-based flu vaccines may be more effective than standard options in seasons affected by egg-adaptation - in which viruses undergo changes when they are grown in eggs, which may reduce the effectiveness of the resulting vaccines in certain seasons.
